Phase IIIb Study of Ribociclib + ET in Early Breast Cancer (Adjuvant WIDER)

Novartis

Status and phase: Begins enrollment this month; Phase 3

Conditions: Early Breast Cancer

Treatments: Drug: Goserelin; Drug: Ansastrozole; Drug: Letrozole; Drug: Leuprolide; Drug: Exemestane; Drug: Ribociclib

Study type: Interventional

Funder types: Industry

Identifiers

NCT05827081

CLEE011O12001

2022-503001-38-00 (Registry Identifier)

Details and patient eligibility

About

The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBCFS), in a close to clinical practice patient population with HR-positive (HR+), HER2-negative (HER2-), Anatomic Stage Group III, IIB, and a subset of Stage IIA Early Breast Cancer (EBC).

Full description

The study consists of Screening, Treatment, and Follow-up periods.

• Treatment Period: all participants who complete screening will receive ribociclib 400 mg orally once daily on days 1 to 21 of a 28-day cycle, in combination with daily ET for 36 months (approximately 39 cycles) from the date of first dose. The Treatment Period starts when the patient receives their first dose of ribociclib and ends at the time of the 30-day Safety Follow-up. All treated participants should have a Safety Follow-up call conducted 30 days after the last dose of study treatment.
• Follow-up period: participants will be followed from 30 days after study treatment (i.e., ribociclib) completion/discontinuation (i.e. 30-day Safety Follow-up) until death, withdrawal of consent, lost to follow-up, or until 48 months after the last participant has received their first dose of study treatment (i.e. End of Study [EOS]), whichever occurs first.

Enrollment: 1,400 estimated patients

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

• Participant has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer (BC).

• Participant has HER2-negative breast cancer.

• Participants may have already received any standard neoadjuvant and/or adjuvant ET, including tamoxifen or toremifene at the time of informed consent signature, but enrollment should occur within 36 months of prior ET start date and participants should have at least 3 years remaining of endocrine adjuvant therapy.

• Participant has no contraindication to receive adjuvant ET in the study.

• Participant after surgical resection where tumor was removed completely, with the final surgical specimen microscopic margins free from tumor, and belongs to one of the following categories:

  • Anatomic Stage Group III, or
  • Anatomic Stage Group IIB, or
  • A subset of Anatomic Stage Group IIA

• Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2.

• Participant has adequate bone marrow and organ function.

• ECG values assessed by KardiaMobile-6L device, or standard 12-lead ECG per local investigator where KardiaMobile-6L cannot be used, as:

  • QTcF interval at Screening < 450 msec (QT interval using Fridericia's correction).
  • Mean resting heart rate 50-99 beats per minute (determined from the ECG).

Key Exclusion Criteria:

• Participant with distant metastases of BC beyond regional lymph nodes (Stage IV according to AJCC 8th edition) and/or evidence of recurrence after curative surgery.
• Participant is concurrently using other antineoplastic therapy with the exception of adjuvant ET.
• Participant has any other concurrent severe and/or uncontrolled medical condition.
• Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality.
• Pregnant or breast-feeding (lactating) women or women who plan to become pregnant or breast-feed during the trial.

Other inclusion/exclusion criteria may apply

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

1,400 participants in 1 patient group

Ribociclib + endocrine therapy

Experimental group

Description:

Participants will receive ribociclib 400 mg orally once daily on days 1 to 21 of a 28-day cycle, in combination with daily endocrine therapy (ET) for 36 months (approximately 39 cycles). ET consists of: * For postmenopausal women: letrozole 2.5 mg orally once daily continuously, anastrozole 1 mg orally once daily continuously, or exemestane 25 mg once daily continuously. * For pre/perimenopausal women, and men: letrozole 2.5 mg orally once daily continuously, anastrozole 1 mg orally once daily continuously, or exemestane 25 mg once daily continuously, combined with goserelin subcutaneously (at 3.6 mg once every 4 weeks if the one-month depot formulation is used or at 10.8 mg once every 3 months if the three-month depot formulation is used) or leuprolide subcutaneously (at 3.75 mg once every 4 weeks if the one-month depot formulation is used or at 11.25 mg once every 3 months if the three-month depot formulation is used)

Treatment:

Drug: Ribociclib

Drug: Exemestane

Drug: Leuprolide

Drug: Letrozole

Drug: Ansastrozole

Drug: Goserelin